MYR Pharma GmbH asserted the completion of MYR 202 Clinical Trial which is a Phase 2b study investigating Myrcludex B in chronic hepatitis Delta patients which is a more acute form of viral hepatitis currently witnessing no optimum treatment options.
It is to be taken into account that 120 subjects were enlisted into MYR 202 in 20 centers in Russia and Germany making it the world’s largest HDV Clinical study. The results of this study will be presented at the General Session of the imminent International Liver Congress, an annual meeting of the European Association for the Study of the Liver (EASL) in Paris, France on April 12, 2018.
Alexander Alexandrov, MD, Chief Medical Officer of MYR Pharma said “The follow-up phase of this study is now completed. This is a very important milestone in the development of Myrcludex B under the PRIME scheme in Europe.”
Myrcludex B is a first-in-class entry inhibitor for the treatment of chronic hepatitis B (HBV) and its co-infection hepatitis Delta. The drug inhibits the recently identified HBV receptor on the hepatocyte surface and prevents the infection of the healthy cells and viral spreading within the liver.